• NewGenIvf priced a reasonable best-efforts public offering targeting gross proceeds of about $1.25 million.
• Deal covers 17,857,143 ordinary shares or pre-funded warrants in lieu of shares.
• Ordinary shares priced at $0.07; pre-funded warrants priced at $0.06999 with a $0.00001 exercise price.
• Closing expected on or about Sept. 30, 2026, subject to customary conditions.
• Net proceeds earmarked for K25.ai investment, debt securities restructuring, working capital, Nodexus machine deployment, corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewGenIvf Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609282230PRIMZONEFULLFEED9835630) on September 29, 2026, and is solely responsible for the information contained therein.